We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher (DHR) to Acquire Abcam, Boost Life Sciences Unit
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) has entered into a definitive agreement to acquire Abcam plc (ABCM) for approximately $5.7 billion (including assumed indebtedness and net of acquired cash). The deal value is equivalent to $24 per share. Following this news, shares of DHR gained 2.3% at the close of business on Aug 28.
Headquartered in Cambridge, UK, Abcam is a global supplier of protein consumables. The company offers highly validated antibodies, reagents, biomarkers and assays that are required for accelerating drug discovery, life sciences research, and diagnostics.
Following the acquisition, Abcam is expected to operate as a standalone company within Danaher's Life Sciences segment.
In the second quarter of 2023, DHR’s Life Sciences segment generated revenues of $1,796 million, up 5.5% year over year. Core sales grew 5.5% year over year. Acquisitions boosted sales by 1%, while unfavorable foreign-currency translations lowered sales by 1%.
Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio are expected to help Danaher solve some of the world's greatest healthcare challenges.
Subject to customary closing conditions, the acquisition is expected to close in mid-2024. Danaher expects to use cash on hand and proceeds from the issuance of commercial paper to fund the transaction.
While Danaher presently carries a Zacks Rank #4 (Sell), Abcam currently holds a Zacks Rank #2 (Buy).
Key Picks
Some better-ranked industrial stocks are as follows:
Flowserve has an estimated earnings growth rate of 79.1% for the current year. The stock has jumped 26.6% so far this year.
Graham Corporation (GHM - Free Report) currently flaunts a Zacks Rank #1. The company pulled off a trailing four-quarter earnings surprise of 243.1%, on average.
Graham has an estimated earnings growth rate of 400% for the current fiscal year. The stock has rallied 65.8% so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Danaher (DHR) to Acquire Abcam, Boost Life Sciences Unit
Danaher Corporation (DHR - Free Report) has entered into a definitive agreement to acquire Abcam plc (ABCM) for approximately $5.7 billion (including assumed indebtedness and net of acquired cash). The deal value is equivalent to $24 per share. Following this news, shares of DHR gained 2.3% at the close of business on Aug 28.
Headquartered in Cambridge, UK, Abcam is a global supplier of protein consumables. The company offers highly validated antibodies, reagents, biomarkers and assays that are required for accelerating drug discovery, life sciences research, and diagnostics.
Following the acquisition, Abcam is expected to operate as a standalone company within Danaher's Life Sciences segment.
Danaher Corporation Price
Danaher Corporation price | Danaher Corporation Quote
In the second quarter of 2023, DHR’s Life Sciences segment generated revenues of $1,796 million, up 5.5% year over year. Core sales grew 5.5% year over year. Acquisitions boosted sales by 1%, while unfavorable foreign-currency translations lowered sales by 1%.
Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio are expected to help Danaher solve some of the world's greatest healthcare challenges.
Subject to customary closing conditions, the acquisition is expected to close in mid-2024. Danaher expects to use cash on hand and proceeds from the issuance of commercial paper to fund the transaction.
While Danaher presently carries a Zacks Rank #4 (Sell), Abcam currently holds a Zacks Rank #2 (Buy).
Key Picks
Some better-ranked industrial stocks are as follows:
Flowserve Corporation (FLS - Free Report) presently sports a Zacks Rank #1 (Strong Buy). The company pulled off a trailing four-quarter earnings surprise of 6.2%, on average. You can see the complete list of today’s Zacks #1 Rank stocks.
Flowserve has an estimated earnings growth rate of 79.1% for the current year. The stock has jumped 26.6% so far this year.
Graham Corporation (GHM - Free Report) currently flaunts a Zacks Rank #1. The company pulled off a trailing four-quarter earnings surprise of 243.1%, on average.
Graham has an estimated earnings growth rate of 400% for the current fiscal year. The stock has rallied 65.8% so far this year.